Skye Bioscience (SKYE) Payables (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Payables of $3.9 million for Q1 2026, up 129.72% year-over-year from $1.7 million in Q1 2025, and up 93.61% quarter-over-quarter from $2.0 million in Q4 2025.
Skye Bioscience (SKYE) Payables (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Payables for 15 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 129.72% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 129.72% YoY), while the FY2025 annual figure was $2.0 million, up 257.21% from the prior year.
- Payables grew to $3.9 million in Q1 2026 per SKYE's latest filing, from $2.0 million in the prior quarter.
- Across five years, Payables topped out at $3.9 million in Q1 2026 and bottomed at $171902.0 in Q4 2022.
- Historically, Payables has averaged $1.6 million across 5 years, with a median of $1.6 million in 2022.
- On a YoY basis, Payables climbed as much as 545.46% in 2022 and fell as far as 82.05% in 2022.
- Skye Bioscience's Payables stood at $171902.0 in 2022, then soared by 456.57% to $956754.0 in 2023, then tumbled by 40.5% to $569252.0 in 2024, then soared by 257.21% to $2.0 million in 2025, then jumped by 93.61% to $3.9 million in 2026.
- Business Quant data shows SKYE's Payables at $3.9 million in Q1 2026, $2.0 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 35.57 Mn |
| 10 | Skye Bioscience | 10.68 Mn | 10.68 Mn | - | 4.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.94 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 569,252.00 |
| Sep 30, 2024 | 780,025.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 956,754.00 |
| Sep 30, 2023 | 1.64 Mn |
| Jun 30, 2023 | 1.66 Mn |
| Mar 31, 2023 | 1.33 Mn |
| Dec 31, 2022 | 171,902.00 |
| Sep 30, 2022 | 2.19 Mn |
| Jun 30, 2022 | 1.55 Mn |
| Mar 31, 2022 | 894,797.00 |
| Dec 31, 2021 | 957,612.00 |
| Sep 30, 2021 | 338,982.00 |
| Jun 30, 2021 | 397,177.00 |